viewMagicMed Industries Inc

MagicMed CEO says firm is riding 'excellent momentum' in developing its Psybrary molecular derivatives library

CEO Joseph Tucker told shareholders that MagicMed believes its Psybrary “is destined to be a vital and enabling platform” for the psychedelics and biotechnology industries

MagicMed Industries Inc -
The firm is expanding and strengthening its management and science teams and filing additional patents

MagicMed Industries Inc CEO Joseph Tucker updated investors on Tuesday about its continued progress developing its Psybrary molecular derivatives library.

In a shareholder letter, Tucker said the firm is expanding and strengthening its management and science teams, filing additional patents and ramping up efforts to establish key biotechnology and pharmaceutical partnerships. 

Tucker told shareholders that Vancouver-based MagicMed believes its Psybrary “is destined to be a vital and enabling platform” for the psychedelics and biotechnology industries.

READ: MagicMed finalizes establishment of patent portfolio for its Psybrary molecular derivatives collection

“We kicked off 2021 with excellent momentum towards the continued expansion of the breadth and depth of the psychedelic derivative portfolios contained in MagicMed’s Psybrary,” Tucker wrote.  

MagicMed’s goal is to have the Psybrary encompass hundreds of millions of psychedelic derivatives based on the structures of psilocybin, DMT, LSD, mescaline, ibogaine, and MDMA. To help achieve this, the company is developing and patenting of additional chemical compound categories. 

According to Tucker, the group initiated candidate selection efforts by synthesizing and analyzing over 200 individual molecules contained in the Psybrary.

“Our partnership with the University of Calgary has provided our industry leading scientists the opportunity to utilize state-of-the-art equipment to test and obtain desired characteristics, such as improved safety profiles and enhanced efficacy,” Tucker wrote.

 “This is an exciting time for the psychedelics industry, as well as for MagicMed, and we are grateful for the opportunity to share our story amongst other industry leaders.”

MagicMed is preparing to list on the Canadian Securities Exchange under the ticker ‘MGIC’, and filed a preliminary prospectus with both the Alberta Securities Commission and the CSE.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: MagicMed Industries Inc


Price: - -

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


MagicMed and Proactive Present Magic Moments Videocast on AI in Psychedelics

Dr. Joseph Tucker, CEO of MagicMed and Steve Darling, Senior Broadcaster from Proactive talk about the use of Artificial Intelligence in the Psychedelpics sector with special guests Richard Dallaway, Founder of April19, and Roshan Bhave, Senior Data Scientist for Cognistx.

on 18/3/21

2 min read